Baldwin Brothers Inc. MA boosted its holdings in shares of DexCom, Inc. (NASDAQ:DXCM) by 1,666.7% during the 3rd quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 636 shares of the medical device company’s stock after acquiring an additional 600 shares during the quarter. Baldwin Brothers Inc. MA’s holdings in DexCom were worth $262,000 at the end of the most recent reporting period.
Other institutional investors and hedge funds have also modified their holdings of the company. IFM Investors Pty Ltd grew its stake in shares of DexCom by 12.3% in the third quarter. IFM Investors Pty Ltd now owns 7,586 shares of the medical device company’s stock worth $3,127,000 after acquiring an additional 831 shares during the last quarter. Sanders Morris Harris LLC acquired a new stake in shares of DexCom in the third quarter worth $396,000. Polaris Wealth Advisory Group LLC grew its stake in shares of DexCom by 8.1% in the third quarter. Polaris Wealth Advisory Group LLC now owns 801 shares of the medical device company’s stock worth $306,000 after acquiring an additional 60 shares during the last quarter. Diversified Trust Co grew its stake in shares of DexCom by 20.7% in the third quarter. Diversified Trust Co now owns 888 shares of the medical device company’s stock worth $366,000 after acquiring an additional 152 shares during the last quarter. Finally, Teamwork Financial Advisors LLC acquired a new stake in shares of DexCom in the third quarter worth $274,000. 97.51% of the stock is currently owned by hedge funds and other institutional investors.
In related news, insider Andrew K. Balo sold 5,256 shares of the business’s stock in a transaction that occurred on Tuesday, September 15th. The stock was sold at an average price of $397.35, for a total value of $2,088,471.60. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, CAO Jereme M. Sylvain sold 600 shares of the business’s stock in a transaction that occurred on Monday, August 24th. The shares were sold at an average price of $427.41, for a total value of $256,446.00. The disclosure for this sale can be found here. Insiders sold a total of 49,918 shares of company stock valued at $20,121,036 over the last quarter. 0.69% of the stock is owned by insiders.
Shares of DexCom stock traded up $5.42 during trading on Friday, hitting $405.00. 838,540 shares of the company were exchanged, compared to its average volume of 1,245,422. The firm has a market capitalization of $38.78 billion, a P/E ratio of 184.93, a price-to-earnings-growth ratio of 3.90 and a beta of 0.79. DexCom, Inc. has a 1-year low of $145.23 and a 1-year high of $456.23. The firm’s fifty day moving average price is $397.78 and its 200 day moving average price is $386.10. The company has a debt-to-equity ratio of 1.23, a current ratio of 7.58 and a quick ratio of 7.17.
DexCom (NASDAQ:DXCM) last issued its quarterly earnings data on Tuesday, July 28th. The medical device company reported $0.79 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $0.31 by $0.48. DexCom had a return on equity of 29.01% and a net margin of 11.93%. The business had revenue of $451.80 million during the quarter, compared to analyst estimates of $415.21 million. During the same period in the previous year, the firm earned $0.08 EPS. DexCom’s quarterly revenue was up 34.3% compared to the same quarter last year. As a group, equities research analysts anticipate that DexCom, Inc. will post 2.67 earnings per share for the current year.
DXCM has been the topic of a number of recent research reports. Zacks Investment Research downgraded shares of DexCom from a “buy” rating to a “hold” rating and set a $430.00 price target on the stock. in a research note on Monday, June 22nd. Cowen lifted their price target on shares of DexCom from $430.00 to $450.00 and gave the stock an “outperform” rating in a research note on Tuesday, July 7th. Piper Sandler lifted their price target on shares of DexCom from $450.00 to $465.00 and gave the stock an “overweight” rating in a research note on Wednesday, July 29th. Bank of America reiterated a “buy” rating and set a $500.00 price target on shares of DexCom in a research note on Tuesday, July 28th. Finally, BidaskClub downgraded shares of DexCom from a “strong-buy” rating to a “buy” rating in a research note on Tuesday, August 25th. One research analyst has rated the stock with a sell rating, five have issued a hold rating and sixteen have issued a buy rating to the stock. DexCom currently has an average rating of “Buy” and a consensus price target of $401.70.
DexCom Company Profile
DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company offers its systems for ambulatory use by people with diabetes; and for use by healthcare providers. Its products include DexCom G6, a CGM system for diabetes management; DexCom G5 mobile CGM system to communicate directly to patient's mobile device; DexCom G4 PLATINUM system for continuous use by adults with diabetes; and DexCom Share, a remote monitoring system.
Recommended Story: How liquidity affects the bid-ask spread
Want to see what other hedge funds are holding DXCM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for DexCom, Inc. (NASDAQ:DXCM).
Receive News & Ratings for DexCom Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DexCom and related companies with MarketBeat.com's FREE daily email newsletter.